GBIO - Generation Bio Co

Recent News

Generation Bio Co. ( GBIO ) Reports Q2 Loss, Misses Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.12

Generation Bio (GBIO) delivered earnings and revenue surprises of -11.43% and -51.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Neutral

Generation Bio Co. ( GBIO ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months, 1 week ago • score: 0.07

Generation Bio (GBIO) delivered earnings and revenue surprises of 12% and 464.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Generation Bio Co., a genetic drug company, develops gene therapies for the treatment of rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts.

52W High

$29.10

52W Low

$3.00

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.49

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

7.68

EV/EBITDA (<8 favorable)

-0.34

EV/Revenue (<3 favorable)

5.10

P/S (TTM) (<3 favorable)

1.90

P/B (<3 favorable)

0.75

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

14.24%

Institutions (25–75% balanced)

62.33%

Shares Outstanding

6,735,500

Float

4,945,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

21,230,000

Gross Profit (TTM)

-26,615,000

EPS (TTM)

-10.84

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-29.28%

ROE (TTM) (>15% strong)

-0.86%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.81

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—